NeuroDerm Ltd. NDRM
Set alert
No live quote for NDRM yet.
- Open
- 38.90
- Prev close
- 38.85
- Mkt cap
- 1.02B
- Vol
- 200.95K
- Avg vol
- 600.48K
- EPS
- -1.98
- P/E
- -19.60
- Div yield
- 0.00%
More statistics
- Low
- 38.85
- High
- 38.95
- Forward P/E
- -19.92
- Beta
- 0.00
- Short ratio
- 1.47
- Inst. own
- 35.24%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 38.90
- 200-d avg
- 32.84
- 1y target
- 47.50
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 892.08M
- Trailing P/E
- -19.60
- Forward P/E
- -19.92
- PEG ratio
- -0.83
- Price / sales
- 0.00
- Price / book
- 7.97
- EPS (TTM)
- -1.98
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -22.22M
- Total cash
- 131.46M
- Total debt
- 0
- Return on equity
- -44.77%
- Shares outstanding
- 26.35M
- Short % of float
- 10.43%
- 50-day average
- 38.90
- 200-day average
- 32.84
Analyst view
Consensus: buy
- Target (low)
- 39.00
- Target (mean)
- 47.50
- Target (high)
- 70.00
Next earnings
Consensus EPS estimate -0.56.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 1, 2017 | Roth Capital | down | Buy | Neutral |
| Jul 20, 2017 | Deutsche Bank | init | — | Buy |
| Jun 13, 2017 | Oppenheimer | up | — | Outperform |
| Mar 6, 2017 | Oppenheimer | down | — | Perform |
| Nov 9, 2015 | Raymond James | init | — | Outperform |
| Apr 22, 2015 | Jefferies | init | — | Buy |
About NeuroDerm Ltd.
NeuroDerm Ltd., a clinical-stage pharmaceutical company, engages in developing drug-device combinations for the treatment of central nervous system (CNS) disorders. The companys levodopa and carbidopa (LD/CD) product candidates, which have completed Phase IIa clinical trial, include ND0612L and ND0612H for the treatment of patients with moderate and advanced Parkinsons disease. It is also developing ND0701, a subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinsons disease and who do not respond well to LD/CD; and ND0801, which is in Phase IIa clinical trial for the treatment of cognition disorders associated with CNS diseases, such as ADD/ADHD, Alzheimers disease, and schizophrenia. NeuroDerm Ltd. was founded in 2003 and is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- neuroderm.com
News
Your note
Sign in to keep a note on NDRM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Scopia Capital Management LP | 16.64% | 4,383,358 | 124.71M | Jun 29, 2017 |
| Menora Mivtachim Holdings Ltd. | 3.07% | 808,073 | 22.99M | Jun 29, 2017 |
| Adage Capital Partners GP L.L.C. | 2.94% | 775,000 | 22.05M | Jun 29, 2017 |
| Viking Global Investors, L.P. | 2.69% | 708,898 | 20.17M | Jun 29, 2017 |
| Franklin Resources, Inc | 2.42% | 636,000 | 18.09M | Jun 29, 2017 |
| Baker Brothers Advisors, LLC | 2.17% | 571,667 | 16.26M | Jun 29, 2017 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Oppenheimer International Small-Mid Company Fund | 1.07% | 283,102 | 6.67M | Feb 27, 2017 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.88% | 232,600 | 6.70M | Apr 29, 2017 |
| Wells Fargo Discovery Fd | 0.86% | 226,100 | 6.43M | Jun 29, 2017 |
| Fidelity Small Cap Growth Fund | 0.76% | 200,000 | 5.76M | Apr 29, 2017 |
| Meridian Small Cap Growth Fund | 0.52% | 137,490 | 3.73M | Mar 30, 2017 |
| iShares MSCI EAFE Small Cap ETF | 0.26% | 67,977 | 1.38M | May 30, 2017 |